Scarica l'app Stockscreener
1.79
7.01%
-0.135
Fate Therapeutics Inc Borsa (FATE) Ultime notizie
Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside - TradingView
Fate Therapeutics stock stands 97.96 percent higher year to date - ad-hoc-news.de
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Singapore
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance UK
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy By Investing.com - Investing.com Nigeria
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy - Investing.com
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com South Africa
Fate Therapeutics appoints Jamie Harrell to lead commercialization - Investing.com
Fate Therapeutics appoints Jamie Harrell to lea... - Pluang
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com Canada
Fate Therapeutics names Jamie Harrell SVP of commercial operations - StreetInsider
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies - GlobeNewswire Inc.
Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan
Fate Therapeutics Appoints Jamie Harrell as Senior Vice - GlobeNewswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Has Consensus Target Price of $5.90 - MarketBeat
Fate Therapeutics grants employee awards: what it means for Fate Therapeutics stock - AD HOC NEWS
Fate Therapeutics stock adds two Q4 conference dates - AD HOC NEWS
Fate Therapeutics stock gained 4.74 percent on October 5 - AD HOC NEWS
Fate Therapeutics (NASDAQ:FATE) Shares Cross Above 50-Day Moving AverageTime to Sell? - marketbeat.com
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Australia
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Two new hires at Fate Therapeutics get stock awards that vest over four years if they stay - stocktitan.net
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics, Inc. (F6T.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire Inc.
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire
FRAUD AND MANIPULATION—S.D. Cal.: Pharma company ducks securities fraud claim for lack of loss causation - VitalLaw.com
Gross profit of Fate Therapeutics, Inc. – HAN:F6T - TradingView
Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial - Yahoo Finance
Fate Therapeutics receives $15m CIRM grant for lupus trial - Investing.com
Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Canada
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative
Fate Therapeutics Announces Receipt of California Institute - GlobeNewswire
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN - Yahoo Finance
Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - Yahoo Finance UK
Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - GlobeNewswire
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - Yahoo Finance
A study explores cell therapy without preparatory chemotherapy. Fate will present four at ACR. - stocktitan.net
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com UK
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com South Africa
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Canada
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com UK
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):